RxDoctor Payments Data

Philip Chui

Interventional Cardiology · Los Angeles, CANPI 1346660461

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,026 of the $5,600 with a category attached, or 71.9%. 15 manufacturers reported payments, led by Abbott at 53.5% of the total. Reporting peaked in 2024 at $3,908 and has fallen 82.7% since, to $677 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.

$5,600in general payments, 2019–2025

Across 103 payments — averaging $54.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$973
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$412
  • Boston Scientific$304
  • Shockwave Medical, Inc$243
  • Biosense Webster, Inc.$136
  • plus $536 from 9 others

What the payments were for

  • Grants$1252%
  • Travel & lodging$1,19821%
  • Food & beverage$4,02672%
  • Education$2514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,600 in reported general payments places this provider in the 35th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024
$159,517
Medicare patients
535
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$67,414
JardianceEmpagliflozin41$45,880
XareltoRivaroxaban33$27,889
BrilintaTicagrelor28$20,179
Metoprolol Succinate153$2,453
ClopidogrelClopidogrel Bisulfate139$1,769
Ranolazine ErRanolazine17$1,491
Atorvastatin Calcium57$1,051
Torsemide59$900
Chlorthalidone37$842
Bumetanide20$802
Isosorbide Dinitrate14$732
Losartan Potassium59$602
Rosuvastatin Calcium43$546
Carvedilol76$542

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →